Pfizer Inc. (NYSE:PFE) Shares Bought by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 229,367 shares of the biopharmaceutical company's stock after acquiring an additional 27,026 shares during the period. HighPoint Advisor Group LLC's holdings in Pfizer were worth $5,457,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter valued at about $2,328,986,000. Starboard Value LP acquired a new stake in Pfizer during the fourth quarter worth $407,730,000. Assenagon Asset Management S.A. increased its stake in Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after acquiring an additional 7,581,030 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. increased its holdings in Pfizer by 1,106.0% in the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after purchasing an additional 5,153,257 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on PFE shares. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Citigroup lifted their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Morgan Stanley increased their price target on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, Bank of America upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Up 0.7%

Shares of PFE stock traded up $0.18 on Wednesday, reaching $25.32. 42,006,966 shares of the company's stock traded hands, compared to its average volume of 41,933,711. The business's 50 day moving average price is $24.07 and its two-hundred day moving average price is $24.71. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $143.98 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 0.88 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm posted $0.82 earnings per share. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.79%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.